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Introduction
 Technological advances are increasingly making it easier to 
collect and analyse Real World Data (RWD)
 RWD gathered in large observational studies is attempting 
to close the gap between experimental, artificial study 
settings and clinical realities.
 Real-world data can complement evidence from controlled 
trials and address questions that trials can’t address –
particularly the performance of a medicine when used in 
clinical practice
Sources of RWD 
 RWD can be collected from 
various sources such as:
• Patient registries 
• Electronic health records
• Insurance databases
• Social media and patient 
research networks
• …
Questions regarding use of RWD and Data 
protection issues
 Are RWD used for research purposes, for reliability and 
safety issues of the products, or is part of a routine patient 
care?
 Which regulations are applicable when processing RWD 
data?
 What is the lawful basis for processing RWD in the 
framework of relevant data protection regulations? 
Status of RWD under the EU General Data Protection
Regulation (GDPR) 
 Only personal data falls under the scope of the GDPR
 Definition of Personal data: 
‘any information relating to an identified or identifiable natural person (“data 
subject”); an identifiable person is one who can be identified, directly or indirectly, in 
particular by reference to an identifier such as a name,  an identification number, 
location data, an online identifier or to one or more factors specific to his physical, 
physiological, genetic, mental, economic, cultural or social identity of that natural person’ 
(Article 4 (1), GDPR)
 Anonymous or annonymized data are not considered as 
personal data
 Pseudonymized or key-coded data are considered as 
personal data 
Patients data and re-identifiability
➢ Individual-level vs. Instituion-
wide health administrative
data
➢ Sharing minimum amount of 
information or aggregate 
data is not identifying  
➢ Re-identifiability of genomic 
data due to linking with 
other databases, etc.. 
Special Categories of Data (Article 9, GDPR) 
 Processing of personal data revealing racial or ethnic origin, 
political opinions, religious or philosophical beliefs, or trade 
union membership, and the processing of genetic data, 
biometric data for the purpose of uniquely identifying a 
natural person, data concerning health or data 
concerning a natural person's sex life or sexual orientation 
shall be prohibited. 
 Processing of special categories requires meeting stricter 
requirements. ( e.g. Data Protection Impact Assessment )
Legal basis for collection and use of RWD 
1. Processing related to reliability and safety issues
II. Research activity
I. Processing related to reliability and safety
issues (Clinical Trials Regulation)
 The processing operations expressly provided by the 
Clinical Trials Regulation (CTR) and by relevant national 
provisions, and which are related to reliability and safety 
purposes, can be considered as falling within “legal 
obligation(s) to which the controller is subject” under 
Article 6(1)(c) of the GDPR. 
 The processing of personal data in the context of safety 
reporting or in the context of an inspection by national 
competent authority, or the retention of clinical 
trial data in accordance with archiving obligations 
set up by the CTR or, as may be the case, relevant 
national laws, have to be considered as necessary to 
comply with legal obligations to which the sponsor and/or 
the investigator are subject to. 
II. Lawful grounds for sharing personal data 
for research purposes  (GDPR)
➢ Research related activities may either fall under:
• The data subject’s explicit consent (Article 6(1)(a) in 
conjunction with Article 9(2)(a)), 
(Note: the informed consent foreseen under the Clinical Trials Regulation must not be 
confused with the notion of consent as a legal ground for the processing of personal 
data under the GDPR. )
• or a task carried out in the public interest (Article 
6(1)(e)), 
• or the legitimate interests of the controller (Article 
6(1)(f)) in conjunction with Article 9(2)(i) or (j) of the 
GDPR.
Sharing data under research exemption rules  
➢ Processing is necessary for archiving purposes in the public 
interest, scientific or historical research purposes or 
statistical purposes in accordance with Article 89(1) based 
on Union or Member State law…(Art. 9(2)(j) in 
conjunction with Art 89 (1))
➢ A borad definition of scientific research (Recital 159) 
➢ Subject to technical and organizational measures 
Safeguards for processing data under research 
exemption 
➢ Technical measures such as pseudonymisation of data to 
mitigate the risks of re-identification 
➢ Models of data sharing and controlled data access: Open 
access vs. controlled access 
➢ To increase accountability of the data controllers and data 
users in access to data 
Data Protection Impact Assessment (Article
35, GDPR) 
The assessment shall contain at least: 
 a systematic description of the envisaged processing operations and the 
purposes of the processing, including, where applicable, the legitimate interest 
pursued by the controller; 
 an assessment of the necessity and proportionality of the processing 
 an assessment of the risks to the rights and freedoms of data subjects
 the measures envisaged to address the risks, including safeguards, security 
measures and mechanisms to ensure the protection of personal data and to 
demonstrate compliance with this Regulation
Discussion and concluding remarks
 Difficult to clearly separate research from clinical practice in 
the context of RWD.  For example, advocates of learning 
health systems have challenged the research-practice 
distinction, but unclear if a new system will be preferable 
and how it satisfies current research regulations
 Use of RWD data in clinical trails: The distinction between 
primary use vs. secondary use is important. 
 Data protection issues are not only addressed by Data 
Protection Officers (DPOs), but ethics committees and 
other oversight bodies also play a role. 
 Despite the enactment/and implementation of EU level 
clincial trials and data protection regulations, still many 
aspects of the data processing is regulated by the relevant 
national laws. 
Thanks for your attention! 
